• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Mabry Adam G

    3/20/26 6:42:13 PM ET
    $JAN
    Get the next $JAN alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    Mabry Adam G

    (Last)(First)(Middle)
    C/O JANUS LIVING, INC.
    4600 SOUTH SYRACUSE STREET, SUITE 500

    (Street)
    DENVER COLORADO 80237

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/20/2026
    3. Issuer Name and Ticker or Trading Symbol
    Janus Living, Inc. [ JAN ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    CHIEF INVESTMENT OFFICER
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit List: Exhibit 24 - Power of Attorney
    No securities are beneficially owned.
    /s/ Carol B. Samaan, Attorney-in-Fact for Adam G. Mabry03/20/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $JAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JAN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $JAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NYSE Content Update: Senior Housing REIT Janus Living to Make Public Debut

    NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, March 20, 2026 /CNW/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Ashley Mastronardi delivers the pre-market update on March 20thMarkets are lower Friday morning after Israeli Prime Minister Benjamin Netanyahu said his country was assisting the U.S. in reopening the Strait of Hormuz.Janus Living (NYSE:JAN) will begin trading on the NYSE today and celebrates its IPO on-site this morning.Guardian Metal Resources CEO & Executive Director Olive

    3/20/26 8:55:00 AM ET
    $ICE
    $JAN
    Investment Bankers/Brokers/Service
    Finance

    Healthpeak Properties and Janus Living Announce Pricing of Upsized $840 Million Janus Living Initial Public Offering

    Healthpeak Properties, Inc. (NYSE:DOC) ("Healthpeak") and Janus Living, Inc. ("Janus Living") announced the pricing of Janus Living's upsized initial public offering ("IPO") of 42,000,000 shares of Janus Living Class A-1 common stock at a price to the public of $20.00 per share. In addition, Janus Living has granted the underwriters a 30-day option to purchase up to an additional 6,300,000 shares of its Class A-1 common stock at the initial public offering price, less the underwriting discount. Janus Living's Class A-1 common stock is expected to begin trading on the New York Stock Exchange on March 20, 2026 under the ticker symbol "JAN." The IPO is expected to close on March 23, 2026, subj

    3/19/26 4:35:00 PM ET
    $DOC
    $JAN
    Real Estate Investment Trusts
    Real Estate

    ALT5 Sigma Corporation Partners With Hashtag Influencer to Enable Cryptocurrency Payment Processing for Influencer Marketing

    LAS VEGAS, NV / ACCESSWIRE / January 15, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS), a prominent innovator in the cryptocurrency sector, is pleased to announce a partnership with Hashtag Influencer, an advanced AI-powered SocialFi platform. This collaboration aims to enhance the influencer marketing landscape by enabling influencers in the gig economy to seamlessly and compliantly accept cryptocurrency payments for advertising deals with brands through social media platforms such as Instagram, Facebook, YouTube, and LinkedIn."While much attention has been given to the adoption of blockchain by traditional institutions, collaborating with innovators such as Hashtag Influencer-a forthcoming A

    1/15/25 7:00:00 AM ET
    $ALTS
    $JAN
    Finance: Consumer Services
    Finance

    $JAN
    SEC Filings

    View All

    SEC Form S-8 filed by JanOne Inc.

    S-8 - Janus Living, Inc. (0002100805) (Filer)

    3/20/26 8:18:24 AM ET
    $JAN

    SEC Form CERT filed by JanOne Inc.

    CERT - Janus Living, Inc. (0002100805) (Filer)

    3/20/26 6:14:23 AM ET
    $JAN

    SEC Form EFFECT filed by JanOne Inc.

    EFFECT - Janus Living, Inc. (0002100805) (Filer)

    3/20/26 12:15:09 AM ET
    $JAN

    $JAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Sandstrom Katherine M

    3 - Janus Living, Inc. (0002100805) (Issuer)

    3/20/26 6:51:17 PM ET
    $JAN

    SEC Form 3 filed by new insider Porter Tracy A

    3 - Janus Living, Inc. (0002100805) (Issuer)

    3/20/26 6:50:21 PM ET
    $JAN

    SEC Form 3 filed by new insider Patadia Ankit B.

    3 - Janus Living, Inc. (0002100805) (Issuer)

    3/20/26 6:48:16 PM ET
    $JAN

    $JAN
    Leadership Updates

    Live Leadership Updates

    View All

    ALT5 Sigma Welcomes FinTech Executive, Ron Pitters to Its Board of Directors

    LAS VEGAS, NV / ACCESSWIRE / November 6, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS) ("ALT5" or the "Company"), a fintech innovator providing next-generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and secure storage of digital assets, is pleased to announce the appointment of Mr. Ron Pitters to its Board of Directors."We are thrilled to welcome industry veteran, Ron Pitters, to our Board. With a unique blend of experience in both traditional finance and disruptive blockchain technologies, Ron brings invaluable insights. His proven track record, spanning from startups to multinational corporations, makes him a fantastic addition to our team,"

    11/6/24 8:30:00 AM ET
    $ALTS
    $JAN
    Finance: Consumer Services
    Finance

    JanOne Appoints Vay Tham as its Chief Revenue Officer and President of its Fintech Subsidiary, ALT5 Sigma

    LAS VEGAS, June 26, 2024 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a multidisciplinary organization with a focus on healthcare and fintech, is pleased to announce that it has appointed Mr. Vay Tham as its Chief Revenue Officer and President of ALT5 Sigma, Inc., its wholly-owned subsidiary. Mr. Tham brings extensive experience in capital markets, particularly in technology sectors, spanning over 25 years. His career includes roles in research, investment banking, and finance, notably and most recently as Managing Director and Head of Technology Investment Banking at PI Financial Corp. (Ventum Financial).

    6/26/24 7:30:00 AM ET
    $JAN

    JanOne Appoints Internationally Renowned Expert on Addiction Nicholas Goeders, Ph.D. to Scientific Advisory Board

    LAS VEGAS, June 15, 2021 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the appointment of Nicholas E. Goeders, Ph.D. to its Scientific Advisory Board (SAB). Dr. Goeders is considered one of the world's leaders on the role of stress in drug addiction.  Tony Isaac, President and Chief Executive Officer of JanOne, commented, "JanOne's mission is to develop non-addictive medications to treat diseases that cause severe pain, thereby m

    6/15/21 10:15:00 AM ET
    $JAN

    $JAN
    Financials

    Live finance-specific insights

    View All

    JanOne Announces Plan to Enhance Stockholder Value Through Strategic Realignment

    -The board has approved a strategic review of the biotech assets and ALT5 Sigma being the core focus going forward- -The company is intending a name and stock symbol change to reflect this decision- LAS VEGAS, July 10, 2024 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a multidisciplinary organization with a focus on fintech and healthcare, has announced plans to enhance stockholder value through a visionary strategic realignment, entailing a redeployment of biotech assets and a change of its name. The plan, unanimously approved by the company's board and following the May acquisi

    7/10/24 8:30:00 AM ET
    $JAN

    JanOne Inc. Completes Acquisition of Soin Therapeutics, LLC

    The acquisition of Soin provides JanOne with its second, late stage clinical stage asset LAS VEGAS, Jan. 10, 2023 /PRNewswire/ -- JanOne Inc. ("JanOne") (NASDAQ:JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that it has completed the acquisition of Soin Therapeutics, LLC and its product, a patent-pending, novel formulation of low-dose naltrexone. This all stock transaction has a value of $13M, with up to an additional $17M depending on revenues generated by the product, for a total value of up to $30M. The transaction includes restrictions on the maximum number of shares of preferred stock and common stock that can be i

    1/10/23 8:30:00 AM ET
    $JAN

    JanOne Inc. Acquires an Option for the Rights to a Worldwide, Exclusive License for a Novel Strategy for Treating Methamphetamine Use Disorder

    LAS VEGAS, Dec. 7, 2021 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties - in an effort to further reduce the drug addiction epidemic - today announced an option agreement for the rights to a novel strategy to reduce methamphetamine (meth) use by activating the Translocator Protein 18 kDa (TSPO).  The agreement with LSU Health Shreveport, along with other intellectual property relating to TSPO's role in treating meth use disorder (MUD), provides JanOne Inc. with an opportunity to identify new drugs to enhance TSPO activity, and by doing so, reducing craving for meth. This new strategy for treating MUD w

    12/7/21 9:00:00 AM ET
    $JAN

    $JAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by JanOne Inc. (Amendment)

    SC 13G/A - JanOne Inc. (0000862861) (Subject)

    8/24/23 4:30:55 PM ET
    $JAN

    SEC Form SC 13G filed by JanOne Inc.

    SC 13G - JanOne Inc. (0000862861) (Subject)

    3/27/23 9:00:21 AM ET
    $JAN

    SEC Form SC 13G/A filed by JanOne Inc. (Amendment)

    SC 13G/A - JanOne Inc. (0000862861) (Subject)

    2/11/22 6:07:45 AM ET
    $JAN